Approximately 70% of patients with JIA who are re-treated with etanercept achieve inactive disease status 12 months after receiving the second course, according to data derived from Klotsche J, et ...

Etanercept alone, or in combination with methotrexate, has greater efficacy than methotrexate monotherapy in patients with psoriatic arthritis, both in terms of ACR20 and minimal disease activity ...

Etanercept, originally developed by Immunex, is currently marketed in the US by Wyeth-Ayerst as Enbrel® for patients with rheumatoid arthritis (RA), where it has been shown to slow the ...

Etanercept was originally developed by Immunex, and is marketed in the US by Wyeth-Ayerst for patients with rheumatoid arthritis, where it has been shown to slow the progression of structural ...

After adjusting for covariates and inverse propensity score matching, participants newly initiating treatment with etanercept (weighted hazard ratio [wHR], 0.72; 95% CI, 0.53-0.97) and ustekinumab ...

Etanercept was associated with lower risk than mono-antibodies for general infections (relative risk, 0.66) with high heterogeneity (I ² = 79 percent).

The global adalimumab, infliximab, etanercept and trastuzumab biosimilars market reached a value of nearly $6.95 billion in 2023, having grown at a compound annual growth rate (CAGR) of 40.20% ...

SAN FRANCISCO, CA—The efficacy and safety profiles of SB4, an etanercept biosimilar, were comparable to those of etanercept in patients with moderate to severe rheumatoid arthritis (RA) to Week ...

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy. These ...

Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Etanercept - Biosimilar Insight, 2024" report has been added to ResearchAndMarkets.com's offering.This "Etanercept - Biosimilar Insight, 2024 ...

Etanercept was associated with lower risk than mono-antibodies for general infections (relative risk, 0.66) with high heterogeneity (I ² = 79 percent).

4.2.1 Published economic evaluations 4.2.1.1 The Assessment Group did not identify any published economic evaluations that considered efalizumab. The Assessment Group identified only one published ...